Publications and Digital Products

This Advisory is based on TIP 55, Behavioral Health Services for People Who Are Homeless. It addresses the fundamentals of how providers and administrators can employ approaches to address the complex challenges of providing integrated treatment services to clients experiencing homelessness.

This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

This updated TIP includes the latest evidence on motivation-enhancing approaches and strategies. It describes how substance use disorder treatment providers can use these approaches and strategies to increase participation and retention in substance use disorder treatment.

This series of four fact sheets emphasizes the importance of continuing a mother's treatment for opioid use disorder (OUD) throughout pregnancy. The series includes information on OUD and pregnancy, OUD treatment, neonatal abstinence syndrome, and considerations to address before hospital discharge.

This fact sheet (1 of 4) gives pregnant women with opioid use disorder (OUD) helpful steps to ensure they have a healthy pregnancy and a healthy baby. This resource includes things to know about OUD and pregnancy, and do's and don'ts to keep mother and baby healthy during pregnancy.

This fact sheet (2 of 4) addresses how treatment of pregnant women with opioid use disorder (OUD) can help women have a healthy pregnancy and a healthy baby. This resource describes managing OUD with a treatment plan that includes medicines and counseling.

This fact sheet (3 of 4) talks about what pregnant women with opioid use disorder should know about and expect after the birth of their baby. This resource includes information about neonatal abstinence syndrome, baby’s needs after birth, and do’s and don’ts for understanding and responding to baby’s needs.